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ABSTRACT: Cancer was recently annexed to diabetic complications. Furthermore, recent studies suggest that cancer
can increase the risk of diabetes. Consequently, diabetes and cancer share many risk factors, but the cellular and
molecular pathways correlating diabetes and colon and rectal cancer (CRC) remain far from understood. In this
study, we assess the effect of hyperglycemia on cancer cell aggressiveness in human colon epithelial adenocarci-
noma cells in vitro and in an experimental animal model of CRC. Our results show that Nox (NADPH oxidase
enzyme) 4–induced reactive oxygen species (ROS) production is deregulated in both diabetes and CRC. This is
paralleledby inactivation of theAMPKand activation of themammalian target of rapamycin (mTOR)C1 signaling
pathways, resulting in 8-oxo-7,8-dihydro-29-deoxyguanosine (8-oxodG) accumulation, induction of DNA damage,
and exacerbation of cancer cell aggressiveness, thus contributing to the genomic instability and predisposition to
increased tumorigenesis in the diabetic milieu. Pharmacologic activation of AMPK, inhibition of mTORC1, or
blockade of Nox4 reduce ROS production, restore the homeostatic signaling of 8-oxoguanine DNA glycosylase/
8-oxodG,and lessen theprogressionofCRCmalignancy inadiabeticmilieu.Taken together,our results identify the
AMPK/mTORC1/Nox4signalingaxis asamolecular switchcorrelatingdiabetes andCRC.Modulating thispathway
may be a strategic target of therapeutic potential aimed at reversing or slowing the progression of CRC in patients
withorwithoutdiabetes.—Mroueh, F.M.,Noureldein,M., Zeidan,Y.H., Boutary, S., Irani,S.A.M., Eid, S.,Haddad,
M., Barakat, R., Harb, F., Costantine, J., Kanj, R., Sauleau, E.-A., Ouhtit, A., Azar, S. T., Eid, A. H., Eid, A. A.
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Diabetes and cancer are prevalent diseases whose in-
cidence rates are increasing worldwide owing to poor
lifestyle practices. Epidemiologic studies show that sub-
jects with diabetes are at a significantly higher risk of
developing many forms of cancer (1–6). In addition to the
development of pancreatic and breast cancer, the in-
cidence of colon and rectal cancers (CRCs) (5, 7, 8) is in-
creased in patients with diabetes.
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Although diabetes (and especially type 2 diabetes) and
cancer share many risk factors, the biologic links between
the 2 diseases are poorly characterized. Diabetes may in-
fluence the neoplastic process through multiple mecha-
nisms, including hyperglycemia (HG), insulin resistance,
and hyperinsulinemia. Although most of the studies
highlight the role of insulin as a risk factor for cancer
progression in diabetes (9–11), little is known about the
role and themechanismsbywhichHG increases the riskof
oncogenesis in diabetes. Several reports associateHGwith
the onset and progression of CRC (12). In fact, increased
levels of glycated hemoglobin were described to be an
independent predictor of CRC aggressiveness in patients
with diabetes (12). Furthermore, it is described that ele-
vated glucose levels in unfed conditions and diabetes are
independent risk factors for the development of cancer in
several tissues, including colon cancer (13). However, in
these studies themechanismscorrelatingHGtoCRConset
and development were not described.
Chronic comorbidities, including diabetes, are impor-
tant characteristics that affect patientswith cancer.Despite
the limited body of evidence, several studies suggest that
cancer can increase the risk of the onset and development
of diabetes (14–21). Patients with CRC showed a higher
incidence of subsequent diabetes than did individuals
without CRC for up to 5 yr after diagnosis (14). Further-
more, in survivors of breast cancer, there was an increase
in the incidence of diabetes among women who were
postmenopausal thatvariedover time. Inmostwomen the
risk began to increase 2 yr after cancer diagnosis (20).
Along the samelines, a recentstudyperformed inaKorean
general population cohort of 524,089 men and women
who were observed for up to 10 yr and developed cancer
showed a clear increase in the subsequent risk of diabetes
independent of traditional diabetes risk factors (15).
Taken together, these studies point to a high association
betweendiabetes and cancer.However, our understanding
of the interplay between the 2 diseases is still fundamental.
Reactive oxygen species (ROS) have evolved as major
players in health and diseases (22–27). It is proposed that
ROS play a crucial role in the progression and severity of
diabetes and are involved in the etiology and progression
of multistage carcinogenesis (22–34). Alongside the mito-
chondria, NADPH oxidase enzymes (Noxes) represent a
leading sourceofROS (31, 32).NADPHoxidases influence
pathways involved in cell and tissue growth, cell signal-
ing, autophagy, and apoptosis (31–33). However, our
understanding of the roles of the Noxes in the interplay
between diabetes and cancer and in regulating several
signaling pathways is limited.
One of the ultimate effects of ROS production is in-
creased DNA damage. ROS induce 8-hydroxylation of
guanine bases, resulting in the production of 8-oxo-7,8-
dihydro-29-deoxyguanosine (8-oxodG). The latter reflects
the intracellular effects of ROS and is considered themajor
indicator of DNA oxidation because of its highmutagenic
potential (35). In the context of CRC, lower levels of 8-
oxodG were described to be associated with longer sur-
vival (36). Similarly, lower levels of 8-oxodG in urinewere
reported to be a good prognostic marker in patients un-
dergoing radiotherapy (37).
The enzyme that recognizes and excises 8-oxodG from
cellular geneticmaterial is 8-oxoguanineDNAglycosylase
(OGG1); however, there is little information on the cellular
andmolecularmechanisms of OGG1 regulation (38). Loss
of heterozygosity at theOGG1 allele leads to loss ofOGG1
function, which in turn contributes to tumorigenesis (39).
Actually, theOGG1 gene is found somatically mutated in
certain cancers (39–43) and is highly polymorphic among
humans. However, the impact of OGG1 polymorphisms
remains poorly investigated.
Our group and others have previously determined that
the energy sensor AMPK is a novel upstream regulator of
Noxes protein expression and activity (23, 26, 44, 45).
AMPK is a known target for themanagement ofmetabolic
syndrome, yet recent roles have emerged for it as a pos-
sible treatment for diabetic complications (23, 46, 47), a
metabolic tumor suppressor, and a target for cancer pre-
vention and treatment (47, 48). These functions are
achieved by restoring the homeostatic function of several
biologic pathways, like autophagy, cellular proliferation,
cell survival, and others (23, 46–48). Despite the scientific
advances in understanding AMPK signaling, the direct
relationship betweenAMPKactivation,Nox4 alteration in
diabetes-induced tumorigenesis, or in cancer stimulating
the onset of diabetes in particular has yet to be established.
The AMPK pathway has been reported to negatively
regulate the mammalian target of rapamycin (mTOR),
which plays a pivotal role in cell growth, cell proliferation,
cell motility, cell survival, and protein synthesis as well as
transcription in response to hormones, growth factors, nu-
trients, energy, and stress signals (49, 50).mTOR is a serine/
threonine protein kinase existing in 2 multiprotein distinct
complexes, mTORC1 andmTORC2 (50). mTORC1 activity
is negatively regulated by the heterodimeric complex con-
sisting of tuberin and hamartin, which in turn are regulated
by theAMPK signaling pathway (50). Ourwork and that of
others demonstrate that deregulated mTORC1 signaling is
implicated in theprogression of cancer anddiabetes (49, 50).
Although many inputs to mTORC1 have now been char-
acterized, the role of mTORC1 in connecting colon tumori-
genesis and diabetes remains largely unclear.
This studywasundertaken todetermine theunderlying
mechanisms that associate diabetes to CRC. The effect of
HG in promoting CRC malignancy in diabetes is in-
vestigated in addition to the interplay between Nox4,
AMPK, and the mTORC1 pathway to identify potential
targets that may reduce or inhibit the onset and progres-
sion of CRC in a high-glucose or diabetic milieu.
MATERIALS AND METHODS
Animal studies
All animal procedureswere conducted according to theGuide for the
Care and Use of Laboratory Animals (National Institutes of Health,
Bethesda,MD,USA)andwereapprovedbytheInstitutionalAnimal
Care and Use Committee at the American University of Beirut.
C57BL/6-Apctm1Tyj/J (APC) 6–8-wk-oldmice, the model of sponta-
neous colon cancer (51) (The Jackson Laboratory, Bar Harbor, ME,
USA), andC57BL/6Jmalemice (control) weighing around 23–25 g
were divided as follows: C57BL/6J mice (control), C57BL/6J mice
14052 Vol. 33 December 2019 MROUEH ET AL.The FASEB Journal x www.fasebj.org
Downloaded from www.fasebj.org by (89.211.130.214) on April 08, 2020. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, pp. 14051-14066.
that received up to 5 consecutive 50 mg/kg body weight in-
traperitoneal injections of streptozotocin (STZ) (Diabetic Complica-
tions Consortium protocol; www.diacomp.org) (52), and APC mice
that received up to 5 consecutive 50 mg/kg body weight in-
traperitoneal injections of STZ (APC-diabetic). The C57BL/6J and
APC mice received similar injections of citrate buffer. Glucose
measurement was performed via tail vein punctures using an
Accucheck glucometer (Roche, Basel, Switzerland). Mice with fast-
ing blood glucose$250 mg/dl were considered diabetic. After the
onset of diabetes, animals were either intraperitoneally given
metformin (150 mg/kg) or rapamycin (0.5 mg/kg) daily or
treated by oral gavage with 40 mg/kg of 2-(2-chlorophenyl)-
4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-
3,6(2H,5H)-dione (GKT), an orally bioavailable low toxicity
compound acting as an inhibitor of NADPH oxidase isoforms 1
and 4 (CaymanChemicals, AnnArbor,MI,USA).All treatments
were administered for 8 wk. After euthanasia, colons were col-
lected and cleaned, and the numbers and size of the polypswere
assessed. Furthermore, part of the colon was either fixed or fro-
zen for histologic molecular and biochemical assessment.
Cell culture and transfection
The human colon carcinoma cell lines HT-29 and CaCo2 were
cultured in 5 mM glucose [normal glucose (NG)] or treated with
25 mM glucose (HG) for 72 h in the presence or absence of 5 mM
metformin or 25 nM rapamycin or their combination. In parallel
experiments, CaCo2 cells cultured in 25 mM of glucose were
treated with the direct AMPK activator 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR) (1mM) (53). For the in vitro
knockout experiments, a clustered regularly interspaced short
palindromic repeats (CRISPR)/CRISPR-associated protein 9
(Cas9) system for Nox4 was used (Santa Cruz Biotechnology,
Dallas, TX, USA). CRISPR (0.1 mg/ml) was introduced into the
cellsusingLipofectamineCRISPRMaxCas9TransfectionReagent
(Thermo Fisher Scientific, Waltham, MA, USA). Control CRISPR
(nontargetingCRISPR, 0.1mg/ml)was used as a negative control.
mRNA analysis
mRNA was analyzed by real-time RT-PCR as previously de-
scribed in refs. 22–25 and 34, and human and mice RT2 quanti-
tative PCR primers (Qiagen, Germantown, MD, USA) of the
corresponding gene of interest were used.
Western blot analysis
Homogenates from cells and colon tissues were prepared, and
Western blotting was performed and analyzed as previously
described in refs. 22–25 and 34. All primary antibodies were
purchased fromCell Signaling Technology (Danvers,MA,USA),
except for the Nox4 (Santa Cruz Biotechnology).
NADPH oxidase activity
NADPH oxidase activity was measured in cells grown in
serum-free medium or in colon tissues homogenates as pre-
viously described in refs. 22–25 and 34.
ROS detection
Cellular H2O2 in colorectal tissues was assessed by dihydroethi-
dium(DHE) fluorescent intensity andvisualizedon confocal laser
scanning confocal microscope (Carl Zeiss, Oberkochen, Ger-
many) and by HPLC analysis (54).
Cellular proliferation
Cellular proliferationwas assessed byMTTCell Proliferation Kit
I (Roche Life Science, Penzberg, Germany) according to the
manufacturer’s protocol.
Wound healing assay
CaCO-2 or HT-29 cells were seeded in 60-mm dishes (Corning,
Corning, NY, USA). Once a confluent monolayer formed, a
scratch was made with a yellow tip (200 ml). After changing the
medium, images of cell movement at different magnifications
were captured using a digital camera mounted on a light mi-
croscope (Carl Zeiss) before and after the 72-h treatment (55).
Cell invasion assay
Invasion assay was performed using the Corning BioCoat
Matrigel Invasion Chamber with Corning Matrigel Matrix fol-
lowing the manufacturer’s instructions.
8-Oxo-29-deoxyguanosine concentration assay
An HT 8-oxo-29-deoxyguanosine (8-oxo-dG) ELISA Kit II
(Trevigen, Gaithersburg, MD, USA) was used to quantify the
level of 8-hydroxy-29-deoxyguanosine in DNA following the
manufacturer’s instructions.
Statistical analysis
Results are expressed asmeansor percentages of the control6 SE.
Statistical significancewas assessedby 1-wayANOVA, followed
by Tukey’s posttest when more than 2 variables were analyzed.
Two group comparisons were performed by a Student’s t test.
Statistical significance was determined as P, 0.05.
RESULTS
HG-induced Nox4-dependent ROS production
alters CaCo2 and HT-29 phenotypes through
an AMPK/mTOR signaling pathway
We have previously highlighted that diabetes or cancer
induces oxidative stress through a Nox4-dependent
mechanism (22–24, 56). We investigated the impact of
HG on CaCo2 and HT-29 cell migration, proliferation,
invasion, and matrix accumulation (Fig. 1A–E and Sup-
plemental Fig. S1A–E). Our data show that the adeno-
carcinomas cell lines increase their migratory phenotype
whenexposed to72hofHG(Fig. 1A,B, andSupplemental
Fig. S1A, B). Additionally, HG increases cellular pro-
liferation rate (Fig. 1C and Supplemental Fig. S1C) and the
potential of these cells to invade the reconstituted base-
ment membrane (Fig. 1D and Supplemental Fig. S1D).
This was also accompanied by an increase in fibronectin
expression known to reflect the extent of migration, in-
vasion, andmetastasis of cancer cells, includingCRC cells
(57) (Fig. 1E and Supplemental Fig. S1E). Notably, our
results show that HG treatment induces AMPK in-
activation (decreases in the AMPK phosphorylation on
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Thr172) in CaCo2 and HT-29 (Fig. 1F and Supplemental
Fig. S1F) and activates the mTORC1/p70S6 kinase path-
way evident by the increased phosphorylation on Ser2448
andThr389, respectively (Fig. 1G,H andSupplemental Fig.
S1G,H). In all our culture experiments,mannitolwasused
as an osmotic control and did not show any effect.
Activation of AMPK or inhibition of mTOR
alleviates HG-induced epithelial
adenocarcinoma cells proliferation,
migration, and invasion and reverses
DNA damage in CaCo2 and HT-29
In order to investigate if the AMPK/mTOR deregulation
correlates with HG-induced epithelial adenocarcinoma
cells proliferation, migration, and invasion, CaCo2 and
HT-29 were treated with HG in the presence or absence
of the AMPK activator, metformin, and the mTORC1
inhibitor, rapamycin, or their combination. Our results
show that in both cell lines, the dose of metformin used
was able to activate the AMPK pathway, as assessed by
the increased phosphorylation on phosphorylated (p)-
AMPKThr172 (Fig. 2A and Supplemental Fig. S2A), and
inhibited the mTORC1/ribosomal protein S6 kinase-b1
(p70S6K) pathway, as assessed by the decreased phos-
phorylation of p-mTORC1Ser2448 and p-p70S6KThr389
(Fig. 2B, C and Supplemental Fig. S2B, C). Rapamycin
treatment had no effect on AMPK phosphorylation
(Fig. 2A and Supplemental Fig. S2A) but reduced
HG-induced p-mTORC1Ser2448 and p-p70S6KThr389 ex-
pression in CaCo2 and HT-29 cells (Fig. 2B, C and
Supplemental Fig. 2B, C), suggesting that mTOR acts
downstream of AMPK.
Furthermore, our results show that treatment with
metformin and rapamycin, significantly alleviates HG-
induced migration, proliferation, and invasion of
CaCo2 and HT-29 (Fig. 2D–H and Supplemental Fig.
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Figure 1. High glucose enhances colon cancer cell migration, proliferation, invasion, and extracellular matrix accumulation. CaCo2 cells
were exposed to NG (5 mM) or HG (25 mM) for 72 h. A) Representative figures of the migration assay performed on CaCo2 cells. B) Bar
graph of the migration assay for CaCo2. C) MTT proliferation assay for CaCo2 cells. D) Cellular invasion assay assessing the number of
CaCo2 cells that invade a porous membrane. E) Bar graph showing quantitation of fibronectin/GAPDH (%). F) Bar graph showing
quantitation of AMPKThr172/AMPK (%). G) Bar graph showing quantitation of p-mTORC1Ser2448/mTORC1 (%). H) Bar graph showing
quantitation of p-p70S6KThr389/p70S6K (%). All values are the means 6 SEM from at least 4 independent experiments. *P , 0.05 vs. NG.
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S2D–H) concomitant with a decline in fibronectin ex-
pression (Fig. 2I and Supplemental Fig. S2I), restitution
of OGG1 protein expression, and attenuation in 8-
oxodG concentrations in both cell lines (Fig. 2J, K and
Supplemental Fig. S2J, K). However, neither additive
nor synergistic effects are seen alongside the use of the
combination treatment (Fig. 2A–K and Supplemental
Fig. S2A–K).
Next, we assessed whether AMPK/mTOR signaling
impacted the adenocarcinoma epithelial cells–enhanced
malignancy through Nox4 in the diabetic milieu. Our re-
sults show that activation ofAMPKor inhibition ofmTOR
reduces HG-induced ROS production in CaCo2 and
HT-29 cells as well as NAPDH oxidase enzyme activity
andNox4mRNA levels andprotein expression (Fig. 2L–O
and Supplemental Fig. S2L–O). Metformin activates
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Figure 2. Activation of AMPK using metformin and inhibition of mTOR reduce cancer cell injury and 8-oxodG production.
CaCo2 cells were treated with HG (25 mM) alone or with AMPK activators, metformin (5 mM) or rapamycin (25 nM) or a
combination of both drugs for 72 h. A) Bar graph showing quantitation of AMPKThr172/AMPK (%). B) Bar graph showing
quantitation of p-mTORC1Ser2448/mTORC1 (%). C) Bar graph showing quantitation of p-p70S6KThr389/p70S6K (%). D)
Representative figures of the migration assay performed on CaCo2 cells. E) Bar graph of the migration assay for CaCo2. F) MTT
proliferation assay for CaCo2 cells. G) Representative figures of the Matrigel invasion assay performed on CaCo2 cells. H)
Cellular invasion assay assessing the number of CaCo2 cells that invade a porous membrane. I) Bar graph showing quantitation
of fibronectin/GAPDH (%). J ) Bar graph showing quantitation of OGG1/GAPDH (%). K) Bar graph showing 8-oxo-dG
accumulation. L) Superoxide anion production measured using HPLC. M) NADPH oxidase activity assay in CaCo2 cells
measured using the Lucigenin assay. N) Relative mRNA amount of Nox4/GAPDH (%), (O) Bar graph showing quantitation of
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AMPK through a direct or indirect manner either by in-
creasing the net phosphorylation of theAMPK catalytica
subunit at Thr172 with subsequent activation of AMPK
activity or by inhibiting the complex 1 of the mitochon-
drial respiratory chain, which results in an increase in the
AMP/ATP or ADP/ATP ratio, leading to AMPK acti-
vation through the binding of either AMP or ADP to
AMPK (58).However, the role of a directAMPKactivator
wasnot investigated. To that end,weusedAICAR,which
is a cell-permeable direct activator of AMPK. AICAR
causes accumulationof 5-aminoimidazole-4-carboxamide
ribonucleoside monophosphate and consequent phos-
phorylation and activation of AMPK without affecting
the cellular ATP/ADP or ATP/AMP ratios (53). Our
results show that the use of AICAR in CaCo2 cells in-
cubated with HG results in similar effects as metformin
(Fig. 3A–M).
Nox4 stimulate cancer cell malignancy in a
diabetic milieu
To further delineate the role of Nox4 in inducing the ma-
lignant phenotype in diabetes, we transfected CaCo2 and
HT-29 cells with Nox4 CRISPR/Cas9 knockout plasmid.
Control CRISPR/Cas9 was also used to evaluate the
specificity of the transfection. Cells transfected with the
Nox4 CRISPR exhibited a reduction in HG-induced ROS
production in CaCo2 and HT-29 (Fig. 4A and Supple-
mental Fig. S3A), which was paralleled with a decrease in
NADPH oxidase activity and the relative mRNA levels
and protein expression of Nox4 (Fig. 4B–D and Supple-
mental Fig. S3B–D). Importantly, knockdown of Nox4
significantly attenuated the HG-induced proliferative,
migratory, and invasive phenotypes as well as the
HG-induced matrix protein accumulation of CaCo2 and
HT-29 (Fig. 4E–H and Supplemental Fig. S3E–I). In-
terestingly, Nox4 inhibition significantly reduced several
observed biochemical and pathologic changes to levels
lower than those observed in adenocarcinoma cells
grown in anNGmedium (Figs. 3 and 4, andSupplemental
Figs. 2 and 3). Taken together, these findings underline the
role of Nox4 as the final common signaling pathway
playing a key role in promoting cancer cell malignancy in
NG or HG.
Diabetes promotes an aggressive malignant
CRC phenotype by altering the
AMPK/mTOR/Nox4 signaling pathway
To confirm our in vitro findings, we used the APC mice
and their control littermates, the C57BL/6J mice. The
C57BL/6J and APC mice were rendered diabetic by
STZ injections [type 1 diabetes mellitus (T1DM) and
T1DM/APC, respectively]. The metabolic characteris-
tics of the mice are highlighted in Table 1. Our results
reveal that the colons of the APC and T1DM/APCmice
have augmented ROS production, NADPH oxidase
activity, and Nox4 mRNA levels and protein expres-
sion when compared with the nondiabetic and T1DM
mice (Fig. 5A–F). As expected, the T1DMmice showed
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significantly higher levels of ROS production, NADPH
activity, and NOX4 mRNA levels and protein expres-
sion when compared with the control mice (Fig. 5A–F).
Furthermore, OGG1 protein expression and 8-oxodG
concentrations were found to be significantly altered in
colon tissues of the APC, T1DM, and T1DM/APCmice
compared with those of the nondiabetic mice, with
more statistically significant alteration in the T1DM/
APC mice (Fig. 5G, H). These observations were par-
alleled by inactivation of AMPK (Fig. 5I, J) and activa-
tion of mTORC1 pathways (Fig. 5K, L) when compared
with the nondiabetic mice. All of these observations
were significantlymore pronounced in the T1DM/APC
mice when compared with both APC and T1DM mice
(Fig. 5A–L). Remarkably, these alterations were con-
comitant with an increase in the proliferation of the
polyps’ number, an increase in the polyp size, and an
increase in fibronectin expression in the colon polyps of
the APC/T1DM mice when compared with APC mice
(Fig. 6A–C). These changes were paralleled by a sig-
nificant increase in CD44 mRNA levels. CD44 mRNA
levels were previously described in refs. 59 and 60 to be
linked to the aggressiveness of CRC and shown to have
the ability to differentiate CRC from other intestinal
tumors.
Up-regulation of Nox4, inactivation of AMPK,
and activation of the mTORC1 fuel the
progression and aggressiveness of the CRC
malignant phenotype
To validate the role of Nox4 and its crosstalkwith AMPK/
mTORC1 in provoking a more pronounced malignant
CRC phenotype in diabetes, the T1DM/APC mice were
either left untreated or treatedwithmetformin, rapamycin,
or GKT, and the results were compared with the APC
nondiabetic mice. Themetabolic characteristics of themice
are highlighted in Table 1. Our results show that diabetes
induces polyps number proliferation, has a tendency to
increase polyp sizes, induces CD44 mRNA levels, and in-
creases fibronectin protein expression (Fig. 6A–D). These
anatomic, histologic, molecular, and biochemical changes
were reversedbymetformin, rapamycin, orGKTtreatment
(Fig. 6A–D). Qualitative analysis of colon tissue sections by
hematoxylin and eosin staining revealed that colons of
T1DM/APC mice displayed microadenoma toward the
surface with a stratification of prominent nuclei migrating
from the basement membrane (Fig. 6E). This was accom-
panied by a decrease in goblet cells and an increase in
number of crypts per surface area, which denoted the
presence of microadenomateous polyps (Fig. 6E). All of
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Figure 3. Activation of AMPK using AICAR reduces cancer cell injury and 8-oxodG production. CaCo2 cells were treated with HG
(25 mM) alone or with AMPK activators AICAR (1 mM) for 72 h. A) Bar graph showing quantitation of AMPKThr172/AMPK (%).
B) Bar graph showing quantitation of p-mTORC1Ser2448/mTORC1 (%). C) Bar graph showing quantitation of p-p70S6KThr389/
p70S6K (%). D) Bar graph of the migration assay for CaCo2. E) MTT proliferation assay for CaCo2 cells. F) Cellular invasion
assay assessing the number of CaCo2 cells that invade a porous membrane. G) Bar graph showing quantitation of fibronectin/
GAPDH (%). H) Bar graph showing quantitation of OGG1/GAPDH (%). I) Bar graph showing 8-oxo-dG accumulation. J )
Superoxide anion production measured using HPLC. K) NADPH oxidase activity assay in CaCo2 cells measured using the
Lucigenin assay. L) Relative mRNA amount of Nox4/GAPDH (%). M) Bar graph showing quantitation of NOX4/GAPDH (%).
EOH, 2-hydroxyethidium; RLU, relative light unit. All values are the means 6 SEM from at least 4 independent experiments. *P ,
0.05 vs. NG, #P , 0.05 vs. HG.
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these changes were not observed in colon sections of the
treated mice (Fig. 6E). Moreover, our results show that
T1DM-inducedROSproduction,NADPHoxidaseactivity,
and Nox4 mRNA levels and protein expression are sig-
nificantly reduced with metformin, rapamycin, or GKT
treatment when compared with APC mice (Fig. 6F–K).
Interestingly, the use of GKT significantly reduced polyp
number, decreased polyp size, abolished diabetes-induced
CD44 mRNA levels, obliterated fibronectin expression,
and loweredNox4-dependentROSproduction in the colon
of the T1DM/APC mice to levels significantly lower than
the baseline levels of the APC mice (Fig. 6A–K).
Next we investigated whether CRC tumorigenesis is
mediated in part by silencing of the OGG1-DNA repair
activity. In fact, OGG1 mRNA expression was rescued
with metformin, rapamycin, and GKT treatment, and
8-oxodG concentrations were attenuated in the colon of
T1DM/APCmicewhen comparedwith APC (Fig. 6L,M).
Remarkably, GKT treatment had a pronounced effect in
restoring the observed changes (Fig. 6L, M).
Collectively, our results indicate that in response to
diabetes, the up-regulation ofNox4, the inactivation of the
AMPK, and the activation of the mTORC1 play a critical
role in theprogression andaggressiveness of the colorectal
malignant phenotype (Fig. 7).
DISCUSSION
Diabetes and cancer are prevalent diseases in the modern
era. Many epidemiologic studies have established fre-
quent cooccurrence of diabetes and cancer, suggesting an
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association of diabetes with specific types of solid tumors,
including CRC tumors (34). In fact, patients with type 2
diabetes have a 20–40% increased risk for colorectal cancer
vs. the general population (28). Likewise, recent studies
revealed that cancer, especially CRC, can increase the risk
of diabetes. PatientswithCRCshowedan increased risk to
develop diabetes than individuals without CRC for up to
5 yr after the diagnosis (14–21).
While diabetes and cancer share many risk factors, the
molecular and cellular mechanisms implicated in their
association are poorly characterized. In this study, we
uncover a novel biologic pathway that links diabetes and
CRC tumorigenesis.
Because mutations in the APC gene are found in more
than 80% of human CRCs, we chose APC mice with a
germlineheterozygousmutation thatmimicshumanCRC
development that is extensivelyused in investigatingbasic
and translational aspects pertaining to CRC (61–63).
It is established that there is an association between
elevated glucose or glycated hemoglobin and the
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Figure 4. Nox4 mediates HG-induced ROS production and cancer cell injury. CaCo2 cells were seeded at low confluence and
subsequently transfected with either control CRISPR or Nox4 CRISPR in the presence or absence of HG (25 mM). A) Superoxide
anion production measured using HPLC. B) NADPH oxidase activity assay on CaCo2 cells. C) Relative mRNA levels of Nox4/
GAPDH (%). D) Bar graph showing quantitation of Nox4/GAPDH (%). E) Bar graph of the migration assay for CaCo2 cells. F)
MTT proliferation assay for CaCo2 cells. G) Invasion assay representing CaCo2 cells’ invasion upon Nox4 knockdown. H) Bar
graph showing quantitation of fibronectin/GAPDH (%). EOH, 2-hydroxyethidium; RLU, relative light unit. All values are the
means 6 SEM from at least 4 independent experiments. *P , 0.05 vs. NG, #P , 0.05 vs. HG.
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predisposition toCRCmalignancies (64, 65).Clinical studies
reported thatpatientswithpoorly controlled type 2diabetes
have more advanced CRCs, a younger age of presentation,
greater use of exogenous insulin, and worse 5-yr survival
(66). However, the signaling pathways correlating diabetes
and CRC are not established. In our studies, CaCo2 and
HT-29 cell lines treated with HG exhibited higher pro-
liferative, migratory, and invasive aptitudes, and that was
attributed to Nox-produced ROS. Studies from our group
and others showed the role of ROS in diabetic nephropa-
thy, neuropathy, retinopathy, and cardiomyopathy (22–26,
67–69).Here,weprovideexcitingevidenceof increasedROS
production, which is demonstrated by elevated O2
2 gener-
ation, in colons of APC mice. This increase appears to be
mediated via a NADPH-dependent mechanism, particu-
larlyNox4. This is in linewith several studies that show that
oxidative stress is involved in carcinogenesis either by en-
hancing genomic instability (70, 71) or inducing DNA mu-
tagenesis (72).More importantly, and for the first time toour
knowledge, we provide evidence for a further increase in
ROS production in the colon of the diabetic APC mice
(T1DM/APC) compared with the nondiabetic APC. These
data corroborate and reinforce the involvement of ROS in
the pathogenic states triggered by diabetes in multiple or-
gans (22–25, 73).
Furthermore, it is established that ROS induce 8-oxodG
production. Here, 8-oxodG adduct formation was ampli-
fied in colons of the APC mice when compared with the
controlmice.Remarkably,wenotedamore significant rise
in the 8-oxodG levels in the colons of theT1DM/APCmice
when comparedwith theAPCmice. These results support
the studies reporting the contribution of ROS over-
production to the risk of genetic mutations in genes in-
volved in cellular dysfunction (74). Indeed, ROS-induced
DNAdamagemay cause misincorporation of DNA bases
due to the presence of unrepaired DNA adducts, for ex-
ample (75). This explains our results that in the diabetic
state, both inAPCandcontrol colon tissuesaswell as in the
adenocarcinoma cell lines, OGG1 mRNA and protein ex-
pressions were down-regulated.
Interestingly, the elevated ROS reported in our study
were concomitant with a significant increase in Nox4
mRNA levels and protein expression in T1DMmice colons
and more pronounced in the T1DM/APC mice. This sug-
gests that Nox4 is responsible, at least in part, for the
generatedROS. In fact,Nox4-mediatedROSare reported to
prevent apoptosis and promote tumor cell growth in pan-
creatic and colon cancer cells (10, 76), further supportingour
hypothesis. Additionally, these findings provide an exten-
sion to our group’s work describing the role of Nox4 in
diabetickidneydiseases (22–24)anddiabetic cardiovascular
disorders (77) and to the research outcomes of others on the
role of Nox4 in diabetic complications (78–80).
To further confirm the role of Nox4 in cancer cell ag-
gressiveness, CaCo2 and HT-29 cells were transfected
withaNox4CRISPRplasmid.Our results show thatNox4
knockdown did not only reduce Nox4 mRNA levels and
protein expression, NADPH oxidase activity, and ROS
production but also significantly abrogated themigratory
and invasive malignant means of cancer cells that were
paralleled by a decrease in the elevated 8-oxodG adducts.
These observations were also confirmed in T1DM/APC
mice, inwhich pharmacologic inhibition of Nox4 byGKT
mitigated the aggressiveness of the malignant phenotype
of theCRC indiabetes. These results are in linewithearlier
findings implicatingNox4 in the pathophysiologyofCRC
by virtue of its ability tomodulate cytoskeletal-regulating
proteins (81) and TGF-b–activated protein tyrosine
phosphatases (82). To our knowledge, this study is the
first to report the implication of Nox4 in colon tumori-
genesis induced by diabetes. Moreover, in this study we
investigated the link betweenNox4andpivotal pathways
of cellular survival, namely the AMPK and mTORC1
pathways. Our findings suggest that AMPK was inacti-
vated in HG in parallel with the Nox4-increased ROS
production. It has been recently reported that under HG,
AMPK may “switch off” in several cell types, thus con-
tributing to the pathogenesis of several disorders, in-
cluding diabetes and cancer (24, 83). Contextually, our
group previously provided evidence that in diabetes,
AMPK activation largely influences kidney function
through reversal of NADPH oxidases–dependent ROS
production (24). Several other studies provide strong ev-
idence that AMPK is involved in tumorigenesis of dif-
ferent types of cancer (48, 84–86). These effects are likely
due to AMPK effects, such as cell cycle arrest and activa-
tionof tumor suppressors (87–89). Besides this, our results
show that mTORC1 was significantly activated in the
T1DM/APC mice as well as in the cultured CaCo2 and
HT-29 cells exposed to HG and that metformin or
TABLE 1. Metabolic characteristics
Group n Blood glucose (mg/dl) Body weight (g)
Control (citrate) 5 151.8 6 11 28.9 6 0.6
STZ-induced T1DM mice 5 522 6 40* 26.5 6 0.2*
STZ-induced T1DM mice + metformin 5 491 6 38* 26.4 6 0.5*
STZ-induced T1DM mice + rapamycin 6 519 6 36* 25.3 6 0.7*
APC mice 5 140 6 18 24.9 6 0.3*
STZ-induced T1DM/APC mice 4 365 6 24# 22.8 6 0.5*,#
STZ-induced T1DM/APC mice + metformin 4 362 6 47# 22.3 6 0.4*,#
STZ-induced T1DM/APC mice + rapamycin 6 435 6 36# 21.9 6 0.4#
STZ-induced T1DM/APC mice + GKT 5 353 6 34# 22.2 6 0.8#
Glucose level and body weight in APC and C57BL/6J control mice: STZ-induced T1DM mice. STZ-induced T1DM mice treated with
metformin (150 mg/kg) or rapamycin (0.5 mg/kg) or GKT for 8 wk after the onset of the disease. Values are the means6 SEM from 4 to 6 animals
for each group. *P , 0.05 vs. control mice. #P , 0.05 vs. APC mice.
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Figure 5. Diabetes promotes an aggressive malignant phenotype in APCmice. A) Representative figures of DHE staining of colon tissues of
different mice groups. B) Bar graph representing ROS production fromDHE staining of colon tissues as assessed by confocal microscopy. C)
Superoxide anion production measured using HPLC. D) NADPH oxidase activity assay on colon tissues. E) Relative mRNA levels of Nox4/
GAPDH (%) in colon tissue. F) Bar graph showing quantitation of Nox4/GAPDH (%) in colon tissue.G) Bar graph showing quantitation of
OGG1/GAPDH (%) in colon tissue. H) Bar graph showing 8-oxo-dG accumulation. I) Relative mRNA levels of AMPK/GAPDH (%) in
colons of different mice groups. J) Bar graph showing quantitation of p-AMPKThr172/AMPK resulting from colon tissue lysates. K) Relative
mRNA levels of mTOR/GAPDH in colons of different mice groups. L) Bar graph showing quantitation of p-mTORC1Ser2448/mTORC1
resulting from colon tissue lysates. Ctr, control; EOH, 2-hydroxyethidium; RLU, relative light unit. All values are the means6 SEM from 4 to 5
mice/group. *P , 0.05 vs. vehicle-treated controls. #P , 0.05 vs. vehicle-treated APC mice, ‘P , 0.05 vs. STZ-induced T1DM mice.
NOVEL CROSSTALK LINKING MTOR AND NOX4 TO DNA DAMAGE 14061
Downloaded from www.fasebj.org by (89.211.130.214) on April 08, 2020. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, pp. 14051-14066.
rapamycin reduced ROS overproduction, NADPH oxi-
dase activity, and Nox4 mRNA and protein levels.
In parallel, the AMPK/mTOR/Nox4 signaling axis
involves OGG1, where OGG1 levels were restored,
whereas 8-oxodG concentrations shied away upon ad-
ministration of the above treatments in vivo and in vitro. In
line with these observations, extensive data from our
group have implicated theAMPK/mTORC1 axis as a key
player in the onset and development of diabetic kidney
diseases (22, 23). In fact, it is suggested that inhibition
of the mTORC1 pathway with rapamycin significantly
reduces NADPH oxidase–dependent oxidative stress,
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Figure 6. Metformin, rapamycin, and GKT treatments reduce diabetes-induced CRC malignancy, attenuate Nox4-produced ROS, and
reverse 8-oxodG adducts in the colons of APC mice. STZ-induced type 1 diabetic APC mice (T1DM/APC) were treated with either vehicle,
metformin (150 mg/kg/d), rapamycin (0.5 mg/kg/d), or GKT (40 mg/kg/d). A) Bar graph showing the percentage of the mean polyp
number in T1DM/APCmice; T1DM/APCmice treated with metformin, rapamycin, or GKT compared with nondiabetic APCmice. B) Bar
graph showing polyp size mean (mm3) in T1DM/APCmice; T1DM/APCmice treated with metformin, rapamycin, or GKT compared with
nondiabetic APC mice. C) Bar graph showing quantitation of fibronectin/GAPDH (%) in colon tissue of the different mice groups. D)
Relative mRNA levels of CD44/GAPDH in colons of the different mice groups (%). E) Representative hematoxylin and eosin–stained
sections of colons of control (Ctr), T1DM/APC mice and T1DM/APC mice treated with metformin. F) Representative images of DHE
stains of colon tissues of different mice groups.G) Bar graph showing the quantitation of the DHE stain assessed by confocal microscopy.H)
Superoxide anion productionmeasured using HPLC. I) NADPH oxidase activity assay from colon tissues. J) Relative mRNA levels of Nox4/
GAPDH (%) in colon tissues of the different mice groups. K) Bar graph showing quantitation of Nox4/GAPDH (%) in colon tissues of the
different mice groups. L) Relative mRNA levels of OGG1/GAPDH (%) in colon tissues of the different mice groups.M) Bar graph showing
8-oxo-dG accumulation in colon tissues of the different mice groups. EOH, 2-hydroxyethidium; Met, metformin; Rapa, rapamycin; RLU,
relative light unit. All values are the means 6 SEM from 4 mice/group. *P , 0.05 vs. the vehicle-treated STZ-induced type 1 diabetic APC
mice. All values are the means6 SEM from 4–5 mice/group. #P, 0.05 vs. vehicle-treated T1DM/APCmice, #P, 0.05 vs. the metformin- or
rapamycin-treated T1DM/APC mice.
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which may have protective effects on the diabetic kidney
(23, 90, 91). Interestingly, inhibition of AMPK and acti-
vation of mTOR in several types of cancer have also been
reported (92, 93). Taken together, our findings highlight a
contributing role for the AMPK/mTORC1 pathway in
CRC progression and tumorigenesis.
In summary, our findings uncover a novel role for
Nox4-induced ROS in promoting DNA damage and
exacerbating tumorigenesis. This is elicited through alter-
ation in the AMPK/mTORC1 pathway, resulting in the
accumulation of 8-oxodG and exacerbating cancer cell
aggressiveness that altogether contribute to the genomic
instability and predisposition to cancer. Consequently,
perhaps a drug combination of Nox4 inhibitors or AMPK
activators and mTORC1 inhibitors along with the stan-
dard anticancer agents may be of therapeutic relevance to
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Figure 6. (Continued)
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alleviate cancer progression in diabetes or to inhibit the
increased risk of diabetes in patients with cancer.
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